A Phase 4, Postmarketing Study Evaluating The Impact Of Prevnar 13 (Trademark)(13-valent Pneumococcal Conjugate Vaccine; 13vpnc) In Reducing Acute Otitis Media And Nasopharyngeal Colonization Caused By Streptococcus Pneumoniae In Healthy Children

Trial Profile

A Phase 4, Postmarketing Study Evaluating The Impact Of Prevnar 13 (Trademark)(13-valent Pneumococcal Conjugate Vaccine; 13vpnc) In Reducing Acute Otitis Media And Nasopharyngeal Colonization Caused By Streptococcus Pneumoniae In Healthy Children

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Otitis media; Pneumococcal infections
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 26 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 04 Jun 2015 Planned End Date changed from 1 Sep 2015 to 1 Mar 2016 as per ClinicalTrials.gov record.
    • 04 Jun 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Mar 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top